Novel Three-Dimensional (3D) Human Kidney Proximal Tubular Epithelial Tissue Model for In Vitro Drug Screening (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0270; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Acute exposure to clinically relevant BMS-986094 (INX-0891), anti-hepatitis C drug that was discontinued during clinical trials due to severe kidney and heart toxicity, resulted in reduced TEER and MTT, in a concentration-dependent manner. A positive control compound Cisplatin and the antifungal medication amphotericin B also decreased TEER and tissue viability while increasing LDH release. In contrast, no adverse effects were noted with the negative control acarbose...Conclusion In summary, the in vitro 3D kidney tissue closely resembles the in vivo human PT region in morphology, barrier function, gene expression, and overall tissue performance. Such a model aligns well with FDA Modernization Act 3.0 guidelines and represents an important advancement in new approach methodologies (NAMs) aimed at identifying adverse renal effects of therapeutic candidates while reducing animal experimentation."
Preclinical • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Renal Disease • AQP1 • CLDN1 • OCLN • TJP1
|
|
Seyoum Ayehunie; Martha R. Mayo; Dylan B. Neale; Mitchell Klausner
|